Table of Contents
- CHAPTER 1 EXECUTIVE SUMMARY
- Objective of the analysis
- Datamonitor insight into the hypertension market
- CHAPTER 2 MARKET DEFINITION AND OVERVIEW
- Market definition and overview for this report
- Hypertension
- Disease overview
- Epidemiology
- Treatment options; the antihypertensive drug classes
- Drugs that inhibit the renin-angiotensin system (RAS)
- Drugs that do not inhibit the renin-angiotensin system (RAS)
- Other classes of antihypertensive drugs
- CHAPTER 3 COUNTRY MARKET ASSESSMENTS
- Current and future opportunities and threats in the antihypertensives
market
- The global market: overview, opportunities and threats
- Overview
- National markets
- The global movers and shakers
- Global opportunities
- Global threats
- US market: overview, opportunities and threats
- Overview
- US market issues
- Japan: overview, opportunities and threats
- Overview
- Japanese market issues
- European Union: overview, opportunities and threats
- Overview
- EU market issues
- CHAPTER 4 FORECAST ANALYSIS
- Assumptions and events
- Ongoing trends
- Increasing market size
- Increasing use of fixed-dose combinations
- Trial results
- New product launches
- S-amlodipine
- SPP100 (aliskiren)
- Caduet
- Patent issues
- ARB patent expiries
- CCB patent expiries
- Beta-blocker patent expiries
- ACE inhibitor patent expiries
- Other patent expiries
- Additional indications
- Irbesartan gains congestive heart failure indication
- Valsartan gains additional diabetes indication
- Methodology
- Forecasts
- CHAPTER 5 COMMERCIAL IMPACT AND LIFECYCLE MANAGEMENT: CASE STUDIES
- Introduction
- Case study 1
- Novartis and the "renin revolution"
- Case study 2
- Clinical trial data and the potential to change prescribing habits
- Case study 3
- EU healthcare reforms: a tale of two countries
- APPENDIX A - MARKET DATA AND MAJOR BRAND KEY FACTS
- Global hypertension market data
- Major brand facts
- C7 BBs
- C8 CCBs
- C9 ACEIs
- C9 ARBs
- Anatomical Therapeutic Chemical (ATC) classification
- APPENDIX B
- Bibliography
- Hypertension management guidelines
- JNC 7
- ESH/ESC
- WHO/ISH
- BHS-IV
- References
- Report methodology
- General
- Japan sales data
- Key opinion leaders
- About Datamonitor
- About Datamonitor Healthcare
- About the Cardiovascular Disease analysis team
- Disclaimer
- Glossary
- APPENDIX C - MARKET FORECAST DATA
- US forecasts
- Japan forecasts
- France forecasts
- Germany forecasts
- Italy forecasts
- Spain forecasts
- UK forecasts
- M5EU forecasts
- Global forecasts
- List of Tables
- Table 1: A comparison of the various forms of hypertension recognized
by three of the key hypertension guidelines
- Table 2: Sales, sales growth and market share of the ARBs in the seven
major markets, 2005
- Table 3: Sales, growth and market share for antihypertensive drug
classes in the seven major markets, 2003-04
- Table 4: ARB sales in the seven major markets, 2004
- Table 5: Prevalence of obesity in the seven major markets by age
(000s), 2003
- Table 6: US sales and growth of antihypertensive drug classes
- Table 7: Japan sales and growth of antihypertensive drug classes
- Table 8: M5EU sales and growth of antihypertensive drug classes
- Table 9: Country-specific sales for antihypertensive drugs in the five
major European countries
- Table 10: Patent expiry dates used in forecasting the antihypertensive
market across the seven major markets
- Table 11: Comparison of hypertension levels from the BHSIV guidelines
and the GMS contract QOF
- Table 12: Coreg: key facts
- Table 13: Toprol-XL: key facts
- Table 14: Tenormin; key facts
- Table 15: Inderal: key facts
- Table 16: Norvasc: key facts
- Table 17: Plendil: key facts
- Table 18: Cardizem LA: key facts
- Table 19: Adalat: key facts
- Table 20: Altace: key facts
- Table 21: Aceon: key facts
- Table 22: Accupro: key facts
- Table 23: Atacand; key facts
- Table 24: Teveten: key facts
- Table 25: Avapro: key facts
- Table 26: Cozaar: key facts
- Table 27: Benicar: key facts
- Table 28: Micardis: key facts
- Table 29: Diovan: key facts
- Table 30: Antihypertensive classifications
- Table 31: US: antihypertensive sales forecasts ($m), 2006-14, with
CAGR between 2004-14 (%)
- Table 32: Japan: antihypertensive sales forecasts ($m), 2006-14, with
CAGR between 2004-14 (%)
- Table 33: France: antihypertensive sales forecasts ($m), 2006-14, with
CAGR between 2004-14 (%)
- Table 34: Germany: antihypertensive sales forecasts ($m), 2006-14,
with CAGR between 2004-14 (%)
- Table 35: Italy: antihypertensive sales forecasts ($m), 2006-14, with
CAGR between 2004-14 (%)
- Table 36: Spain: antihypertensive sales forecasts ($m), 2006-14, with
CAGR between 2004-14 (%)
- Table 37: UK: antihypertensive sales forecasts ($m), 2006-14, with
CAGR between 2004-14 (%)
- Table 38: M5EU: antihypertensive sales forecasts ($m), 2006-14, with
CAGR between 2004-14 (%)
- Table 39: Global: antihypertensive sales forecasts ($m), 2006-14, with
CAGR between 2004-14 (%)
- List of Figures
- Figure 1: Prevalence of hypertension broken down by age, 2004-15
- Figure 2: The renin-angiotensin system
- Figure 3: Angiotensin II is a cardiovascular risk factor with direct
tissue effects
- Figure 4: Recommendations for the combining of blood pressure lowering
drugs (AB/CD rule) (adapted from Williams et al., 2004)
- Figure 5: Pharmaceutical sales in the seven major markets, 2004
- Figure 6: Market share by antihypertensive class, 2001 and 2004 in the
seven major markets
- Figure 7: Sales, growth and market share for antihypertensive drug
classes in the seven major markets, 2003-04
- Figure 8: Global sales values for the antihypertensive classes, 2001-04
- Figure 9: Average ex-manufacturer prices of the leading brands of each
antihypertensive class across all country markets, 2001-04
- Figure 10: Share of antihypertensives market represented by each of
the seven major markets, 2004
- Figure 11: Proportion of population aged 20-39 years, 2004 and 2015,
and prevalence of hypertension in this age group in the seven major
markets, 2004
- Figure 12: Proportion of population aged 40-59 years, 2004 and 2015,
and prevalence of hypertension in this age group in the seven major
markets, 2004
- Figure 13: Proportion of population aged 60-79 years, 2004 and 2015,
and prevalence of hypertension in this age group in the seven major
markets, 2004
- Figure 14: Annual US sales of antihypertensive drug classes, 2001-04
- Figure 15: JNC6 and JNC7 compared; classification of blood pressure
levels
- Figure 16: Compelling indications for individual drug classes
- Figure 17: Annual Japanese sales of antihypertensive drug classes,
2001-04
- Figure 18: Annual M5EU sales of antihypertensive drug classes, 2001-04
- Figure 19: Unlike the ARBs, SPP100 produces significant Reductions in
plasma renin activity (PRA)
- Figure 20: Clinical development activity with SPP100 (aliskiren), 2005
- Figure 21: Speedel's Phase II study on SPP100
- Figure 22: Novartis's Phase IIb study on SPP100 (Study 2201)
- Figure 23: Systolic blood pressure (SBP) reductions during Novartis's
SPP100 plus Diovan study (Study 2203)
- Figure 24: Diastolic blood pressure (DBP) reductions during Novartis's
SPP100 plus Diovan study (Study 2203)
- Figure 25: SPP100; building the brand & differentiating it in the
market
- Figure 26: ASCOT study design
- Figure 27: ASCOT trial profile
- Figure 28: Domestic and Foreign Sales of German Pharmaceutical
Companies
- Figure 29: QOF eleven clinical areas (points)
- Figure 30: The impact of healthcare reforms in Germany on sales growth
within the antihypertensive drug market
- Figure 31: The impact of healthcare reforms in the UK on sales growth
within the antihypertensive drug market
|
Related Report
|
View Cart
